Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog composed of a stabilized amino acid sequence designed to interact with GHRH receptor pathways. It is commonly utilized in research settings to study metabolic signaling, lipid metabolism pathways, and endocrine system dynamics. Supplied by Peptico for research-use only.
All Orders Ship within
24 Business Hours
Free Shipment Protection
Priority Shipment Options Available at Checkout
- For maximum potency, lyophilized materials may generally be stored between 2°C and 8°C (36°F to 46°F) for up to 4 weeks when maintained in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
- For maximum potency and long-term preservation, lyophilized materials may generally be stored between -20°C and -80°C (-4°F to -112°F) for up to 1 year when preserved in their original, sealed lyophilized form.
- Maintain a cool and dry environment.
- Protect from moisture and light.
- Minimize exposure to humidity and temperature fluctuations.
Important Note:
Storage guidelines apply only to lyophilized material in its original, sealed, and untampered vial.
COA History
All shipped products include a unique batch number printed on the vial label. This batch number corresponds to a third-party Certificate of Analysis tested by an ISO/IEC 17025 accredited laboratory.
The COA attached at the top of this page, along with the COA marked “Current” below, represents the active production batch currently being shipped. This same batch number will appear on the label of your vial.
For previous purchases, please refer to COAs marked “Historical” and match the batch number on your vial to the batch number listed on the corresponding COA.
For a complete record of testing documentation across all products and batches, please visit our COA Vault, which includes both current and historical COAs.
Molecular Profile
What is Tesamorelin?
Scientific compound data sourced from PubChem.
Research
Sources & References
API results related to Tesamorelin.
Tesamorelin compound record
CID: 16137828
(4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
Formula: C221H366N72O67S • Molecular weight: 5136
View sourceInjectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
JBJS reviews
Villegas Meza AD, Nocek M, Mitchell BC et al. • 2026
Publication date: 2026 May 1
View sourceDiffering Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Beach R, Tims-Cook Z, McGary CS et al. • 2026
Publication date: 2026 May 15
View sourceTherapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
International journal of molecular sciences
Renke G, Chinellato L • 2026
Publication date: 2026 Apr 27
View sourceCombined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
Chege BM, Mwangi PW, Githinji CG et al. • 2026
Publication date: 2026
View sourceSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.)
Mendias CL, Awan TM • 2026
Publication date: 2026 Apr 12
View source⚠️ IMPORTANT RESEARCH NOTICE
This product is NOT for human consumption.
Supplied strictly for laboratory and analytical research use only, it is not intended to diagnose, treat, cure, or prevent any disease, and must not be used for clinical, veterinary, or therapeutic applications.
All information provided, including referenced research and data, is for educational and scientific context only and should NOT be interpreted as medical guidance.
By purchasing, you confirm that you are a qualified individual or entity operating in accordance with applicable local, state, and federal regulations. All responsibility for handling, use, and compliance rests solely with the purchaser.





